CD8A and neoplasm: Moreover, we stratified patients from cohort I according to PKP3 abundance and the number of CD8+ TILs in the tumor region into three groups (group 1: low PKP3/high TILs; group 2: low PKP3/low TILs or high PKP3/high TILs; and group 3: high PKP3/low TILs).